Mechanism of Drug-drug Interaction Between Salvianolate Injection and Aspirin

Sponsor

Xiyuan Hospital of China Academy of Chinese Medical Sciences (Other)

Overall Status

Unknown status

CT.gov ID

NCT03306550

Collaborator

(none)

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The combination of anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease. However, the material foundation, effective mechanism and drug-drug interaction is still not clear. In order to solve the puzzle of rational use of Joint application by TCM and Western Medicine(WM),investigators conduct a research on mechanism of drug-drug interaction between salvianolate injection and aspirin based on metabolic enzyme and PK-PD model. This clinical trial contain three groups, aspirin group, salvianolate injection group and combination (salvianolate injection+aspirin) group. Investigators collect blood samples at special time points during post-administration.Investigators have already find out the Salvianolate's pharmacokinetic characteristics in vivo and establish the biological sample-testing analysis method in previous research. Depending on these results, this clinical trial aim to explore the pharmacodynamics-pharmacokinetics(PK-PD) characteristics of combination with Salvianolate and aspirin through biomarkers, blood concentration. Finally clarify the TCM and WM material basis and mutual mechanism of drug interaction and guide reasonable clinical prescription.

Condition or Disease	Intervention/Treatment	Phase
Angina, Stable	Drug: salvianolate injection Drug: Aspirin Tablet	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

18 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Research on Mechanism of Drug-drug Interaction Between Salvianolate Injection and Aspirin Based on the Metabolic Enzyme and PK-PD Model

Anticipated Study Start Date :

Oct 10, 2017

Anticipated Primary Completion Date :

Apr 10, 2018

Anticipated Study Completion Date :

Oct 10, 2018

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: aspirin arm only take aspirin (100mg,qd) orally for 10 days treatment course	Drug: Aspirin Tablet Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
Active Comparator: salvianolate injection arm only inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course	Drug: salvianolate injection The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.
Experimental: aspirin and salvianolate injection arm take aspirin (100mg,qd) orally and inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course	Drug: salvianolate injection The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease. Drug: Aspirin Tablet Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.

Arm

Intervention/Treatment

Active Comparator: aspirin arm

only take aspirin (100mg,qd) orally for 10 days treatment course

Drug: Aspirin Tablet

Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.

Active Comparator: salvianolate injection arm

only inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course

Drug: salvianolate injection

The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.

Experimental: aspirin and salvianolate injection arm

take aspirin (100mg,qd) orally and inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course

Drug: salvianolate injection

Drug: Aspirin Tablet

Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.

Outcome Measures

Primary Outcome Measures

Change of P-selection expression(platelet activation-dependent granule membrane) at different time points. [Getting blood sample before taking medicine in the day 10 and after it in 15min、1h、2h、8h、24h]
Use flow cytometric method to detect the P-selection expression on platelet at different time points. Analyse the influence of Asprin/Salvianolate on platelet interaction adhesion during drug concentration-time curves.
Change of PAC-1 expression (platelet-associated complement) on the activated platelets at different time points. [Getting blood sample before taking medicine in the day 10 and after it in 15min、1h、2h、8h、24h]
Use flow cytometric method to detect the PAC-1 expression on platelet at different time points. Analyse the influence of Asprin/Salvianolate on platelet aggregation during drug concentration-time curves.
Change of P2Y12 acceptor expression on platelets at different time points. (P2Y12 acceptor is a receptor for ADP(adenosine diphosphate) and ATP (adenosine triphosphate )coupled to G-proteins that inhibit the adenylyl cyclase second messenger system) [Getting blood sample before taking medicine in the day 10 and after it in 15min、1h、2h、8h、24h]
Use flow cytometric method to detect the P2Y12 acceptor expression on platelet at different time points. Analyse the influence of Asprin/Salvianolate on platelets aggregation activated by ADP or ATP during drug concentration-time curves.
Change of PDE enzymes（phosphodiesterase）expression on platelet at different time points. [Getting blood sample before taking medicine in the day 10 and after it in 15min、1h、2h、8h、24h]
Use ELISA method to detect the PDE enzymes expression at different time points. Analyse the influence of Asprin/Salvianolate on platelets activated by PDE enzymes during drug concentration-time curves.

Secondary Outcome Measures

Change of Aspirin esterase activity at different blood concentration of Asprin/Salvianolate [Getting blood sample before taking aspirin in day 8 and day 9.In the day 10, getting blood sample before taking aspirin and after taking aspirin in 5min、15min、30min、45min、1h、2h、4h、8h、12h、24h]
Conduct biological analysis by LC-MS/MS(liquid chromatography tandem mass spectrometry) to detect Aspirin and salicylic aspirin and salicylic acid:CSA/C(ASA+SA).The activity of combination arm and of the asprin arm is compared by t test.
Change of Catechol-o-methyltransferase (COMT) activity at different blood concentration of Asprin/Salvianolate [Getting blood sample before injection in day 8 and day 9.In the day 10, getting blood sample before injection and after injection in 5min、15min、30min、45min、1h、2h、4h、8h、12h、24h]
COMT activity is the main metabolic enzymes of SAB.Use kit to detect COMT activity .

Eligibility Criteria

Criteria

Ages Eligible for Study:

35 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Meet the diagnostic criteria of coronary heart disease.
Meet the diagnostic criteria of stable angina pectoris.
Meet the diagnostic criteria of syndrome of blood stasis.
Angina in grade I-II according to Canadian cardiovascular society (CCS).
It could be enrolled if the subject taking aspirin or salvianolate injection with one month regularly。
The subjects were informed and voluntarily signed informed consent.

Exclusion Criteria:

Severe heart disease (acute myocardial infarction of acute myocardial infarction in 6 months), severe cardiopulmonary dysfunction (eg: cardiac function II)
Poorly controlled hypertension(systolic pressure >160mmHg or diastolic pressure

100mmHg).

Diabetics.
Severe primary diseases such as liver and renal hematopoietic system damage. Such as:liver function（ALT≥2×ULN、AST≥2×ULN）,kidney function（Cr>1.0×ULN) or nervous and mental disorder.
Pregnant, breast-feeding and menstrual women, or women planning pregnancy within 3 months.
Subjects who participated in clinical trials in recent 3 months.
Subjects who took surgery treatment or had hemorrhagic tendency in recent 4 weeks.
Subjects who had drug allergy history or with allergic constitution.
Subjects who has mental or physical disorders.
Subjects who had bad compliance or is not suitable for this clinical trial by investigator's judgement